EA032953B1 - Нафтиридиновые соединения в качестве ингибиторов jak киназы - Google Patents

Нафтиридиновые соединения в качестве ингибиторов jak киназы

Info

Publication number
EA032953B1
EA032953B1 EA201792619A EA201792619A EA032953B1 EA 032953 B1 EA032953 B1 EA 032953B1 EA 201792619 A EA201792619 A EA 201792619A EA 201792619 A EA201792619 A EA 201792619A EA 032953 B1 EA032953 B1 EA 032953B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
kinase inhibitors
jak kinase
naphthyridine compounds
inhibitors
Prior art date
Application number
EA201792619A
Other languages
English (en)
Other versions
EA201792619A1 (ru
Inventor
Райан Хадсон
Дженнифер Козак
Пол Р. Фазери
Данте Д. Подесто
Гари И.л. Брандт
Мелисса Флери
Анн-Мари Босолей
Сяоцзюнь Хуан
Венкат Р. Таллади
Original Assignee
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи filed Critical ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Publication of EA201792619A1 publication Critical patent/EA201792619A1/ru
Publication of EA032953B1 publication Critical patent/EA032953B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Изобретение обеспечивает соединения формулы (I)где переменные определены в описании изобретения, или их фармацевтически приемлемые соли, которые являются ингибиторами JAK киназ. Изобретение также обеспечивает фармацевтические композиции, включающие такие соединения, способы применения таких соединений для лечения воспалительных заболеваний кишечника, способы и промежуточные соединения для получения таких соединений.
EA201792619A 2015-05-28 2016-05-26 Нафтиридиновые соединения в качестве ингибиторов jak киназы EA032953B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562167694P 2015-05-28 2015-05-28
US201662312273P 2016-03-23 2016-03-23
PCT/US2016/034243 WO2016191524A1 (en) 2015-05-28 2016-05-26 Naphthyridine compounds as jak kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201792619A1 EA201792619A1 (ru) 2018-04-30
EA032953B1 true EA032953B1 (ru) 2019-08-30

Family

ID=56118022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792619A EA032953B1 (ru) 2015-05-28 2016-05-26 Нафтиридиновые соединения в качестве ингибиторов jak киназы

Country Status (31)

Country Link
US (5) US9725470B2 (ru)
EP (2) EP3569604B1 (ru)
JP (4) JP6692836B2 (ru)
KR (1) KR20180011272A (ru)
CN (2) CN107667108B (ru)
AU (2) AU2016267141B2 (ru)
BR (1) BR112017025542A2 (ru)
CA (1) CA2983453A1 (ru)
CL (1) CL2017002994A1 (ru)
CO (1) CO2017012267A2 (ru)
CY (1) CY1122279T1 (ru)
DK (1) DK3303348T3 (ru)
EA (1) EA032953B1 (ru)
ES (2) ES2753159T3 (ru)
HK (1) HK1245771A1 (ru)
HU (1) HUE046130T2 (ru)
IL (3) IL255358B (ru)
LT (1) LT3303348T (ru)
ME (1) ME03610B (ru)
MX (2) MX2017015211A (ru)
PH (1) PH12017502050A1 (ru)
PL (1) PL3303348T3 (ru)
PT (1) PT3303348T (ru)
RS (1) RS59522B1 (ru)
SA (1) SA517390337B1 (ru)
SG (1) SG10201910742VA (ru)
SI (1) SI3303348T1 (ru)
TW (2) TWI704152B (ru)
UA (1) UA121138C2 (ru)
WO (1) WO2016191524A1 (ru)
ZA (1) ZA201707326B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032953B1 (ru) 2015-05-28 2019-08-30 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Нафтиридиновые соединения в качестве ингибиторов jak киназы
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
KR102244257B1 (ko) 2016-04-28 2021-04-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
BR112019011968A2 (pt) 2016-12-16 2019-11-05 Janssen Pharmaceutica Nv inibidores de pequenas moléculas da família jak de quinases
IL274037B2 (en) * 2017-10-27 2023-11-01 Theravance Biopharma R& D Ip Llc A pyrimidine compound as a JAK kinase inhibitor
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111601804A (zh) * 2018-11-27 2020-08-28 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
CN116003441A (zh) * 2018-11-30 2023-04-25 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3958969B1 (en) 2019-04-24 2024-01-10 Theravance Biopharma R&D IP, LLC Ester and carbonate pyrimidine compounds as jak kinase inhibitors
CA3135388A1 (en) * 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144366A (zh) * 2020-05-25 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 雜芳類衍生物的鹽、晶型及其製備方法
WO2022076714A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solid forms of a pan-jak inhibitor
JP2023545333A (ja) 2020-10-09 2023-10-27 セラバンス・バイオファーマ・アールアンドディー・アイピー・エルエルシー 汎ｊａｋ阻害物質及び関連する中間化合物を調製するプロセス
US11795180B2 (en) * 2020-10-09 2023-10-24 Theravance Biopharma R&D Ip, Llc Formulation of a pan-JAK inhibitor
WO2022076717A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Solvate forms of a pan-jak inhibitor
WO2022165529A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
WO2022241188A1 (en) 2021-05-14 2022-11-17 Theravance Biopharma R&D Ip, Llc Enantioselective synthesis of aminotropane compound
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
WO2023102800A1 (en) 2021-12-09 2023-06-15 Theravance Biopharma R&D Ip, Llc Synthesis of 5, 7-dichloro-1, 6-naphthyridine
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
WO2007071348A1 (en) * 2005-12-19 2007-06-28 F. Hoffmann-La Roche Ag Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005606A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2010002472A1 (en) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
CA2737217A1 (en) 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CN105367555B (zh) 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EA032953B1 (ru) 2015-05-28 2019-08-30 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Нафтиридиновые соединения в качестве ингибиторов jak киназы
KR102244257B1 (ko) 2016-04-28 2021-04-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 피리미딘 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
WO2007071348A1 (en) * 2005-12-19 2007-06-28 F. Hoffmann-La Roche Ag Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors

Also Published As

Publication number Publication date
US20180354974A1 (en) 2018-12-13
WO2016191524A1 (en) 2016-12-01
JP2018515581A (ja) 2018-06-14
LT3303348T (lt) 2019-11-25
JP2020111593A (ja) 2020-07-27
HUE046130T2 (hu) 2020-02-28
ES2753159T3 (es) 2020-04-07
IL272057B (en) 2020-09-30
US9725470B2 (en) 2017-08-08
TWI746178B (zh) 2021-11-11
AU2020202181A1 (en) 2020-04-16
CN107667108A (zh) 2018-02-06
TW202108593A (zh) 2021-03-01
IL255358A0 (en) 2017-12-31
SA517390337B1 (ar) 2021-03-31
ZA201707326B (en) 2018-11-28
CO2017012267A2 (es) 2018-03-28
US11780852B2 (en) 2023-10-10
EP3569604B1 (en) 2022-07-06
US20170305934A1 (en) 2017-10-26
MX2020011774A (es) 2021-06-01
US20200040010A1 (en) 2020-02-06
US20160347772A1 (en) 2016-12-01
IL276677B (en) 2021-05-31
SG10201910742VA (en) 2020-01-30
EP3569604A1 (en) 2019-11-20
US20210179637A1 (en) 2021-06-17
IL276677A (en) 2020-09-30
JP6942853B2 (ja) 2021-09-29
CN111362975A (zh) 2020-07-03
PL3303348T3 (pl) 2020-02-28
PH12017502050B1 (en) 2018-04-23
CL2017002994A1 (es) 2018-03-09
CN111362975B (zh) 2022-04-05
BR112017025542A2 (pt) 2018-08-07
US10072026B2 (en) 2018-09-11
EP3303348B1 (en) 2019-08-07
HK1245771A1 (zh) 2018-08-31
PH12017502050A1 (en) 2018-04-23
RS59522B1 (sr) 2019-12-31
SI3303348T1 (sl) 2019-12-31
PT3303348T (pt) 2019-11-15
JP2021098757A (ja) 2021-07-01
ES2924698T3 (es) 2022-10-10
MX2017015211A (es) 2018-04-13
US10494382B2 (en) 2019-12-03
CA2983453A1 (en) 2016-12-01
JP6850922B2 (ja) 2021-03-31
DK3303348T3 (da) 2019-11-11
EP3303348A1 (en) 2018-04-11
AU2016267141A1 (en) 2017-11-16
AU2016267141B2 (en) 2020-04-16
US10947254B2 (en) 2021-03-16
CN107667108B (zh) 2020-05-12
IL255358B (en) 2020-01-30
CY1122279T1 (el) 2020-10-14
ME03610B (me) 2020-07-20
EA201792619A1 (ru) 2018-04-30
JP6692836B2 (ja) 2020-05-13
JP2021001196A (ja) 2021-01-07
TWI704152B (zh) 2020-09-11
AU2020202181B2 (en) 2021-07-01
UA121138C2 (uk) 2020-04-10
TW201716416A (zh) 2017-05-16
KR20180011272A (ko) 2018-01-31
IL272057A (en) 2020-02-27

Similar Documents

Publication Publication Date Title
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
PH12017502203A1 (en) Tyrosine kinase inhibitors
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
MD4800B1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2016010106A (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
PH12017501063A1 (en) Compounds for the treatment of cancer
MY192305A (en) Bipyrazole derivatives as jak inhibitors